A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Isoniazid

Antimycobacterial class · 5 generic manufacturers · 7 ANDAs filed at FDA.

First FDA approval1972-09-01
Generic availableYes · 5 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$735,222 in CY2024 Part D spend53K claims · 20K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.65/unit
14 NDCs benchmarked, lowest of all strengths.
Average NADAC
$2.89
Across all dosage forms in distribution.
Highest NADAC
$3.23
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Isoniazid used for?

Isoniazid is a Antimycobacterial medication tracked in Medicare Part D.

Is there a generic for Isoniazid?

Yes. 7 ANDAs filed at FDA, 5 generic manufacturers currently shipping.

How much does my plan pay for Isoniazid?

Across 329 Part D plans, Isoniazid averages $2.89/unit (NADAC). Lowest available: $1.65/unit. Highest in distribution: $3.23/unit.

Is Isoniazid on the FDA shortage list?

Isoniazid has been discontinued by its manufacturer(s).

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Antimycobacterial3 alternatives in D1
01
Pretomanid
Antimycobacterial
Lowest NADAC
0Generic mfrs
$96,750CY24 Part D spend
Compare →
02
Pyrazinamide
Antimycobacterial
$1.62Lowest NADAC
3Generic mfrs
$932,539CY24 Part D spend
Compare →
03
Pyrazinamide Tablet
Brand: PYRAZINAMIDE
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (7 approvals on file) · NADAC unit costs: CMS NADAC weekly file (14 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.